Core Laboratories (CLB) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue was $129.2 million, down 4% sequentially but up slightly year-over-year; full-year revenue reached $523.8 million, up 2.8% from 2023.

• Full-year operating income (ex-items) was $65.3 million, up 7% year-over-year; full-year EPS (ex-items) was $0.87, up 9%.

• Free cash flow for 2024 was $43.4 million, up over 200% from 2023; Q4 FCF was $16.2 million, up over 50% sequentially.

• Debt leverage ratio improved to 1.31, the lowest in over eight years, with net debt reduced by $42 million in 2024.

• Strategic focus remained on technology investments, operational efficiency, and geographic expansion, despite headwinds from geopolitical conflicts and sanctions.

Financial highlights

• Q4 operating income (GAAP) was $14.2 million; full-year EBIT ex-items was $65.3 million, up 7% year-over-year.

• Q4 net income ex-items was $10.4 million; full-year net income ex-items was $41.6 million, up 10% from 2023.

• Q4 EPS ex-items was $0.22; full-year EPS ex-items was $0.87, up 9% year-over-year.

• Q4 share repurchases totaled 264,982 shares for $4.9 million.

• Quarterly dividend of $0.01 per share announced for Q1 2025.

Outlook and guidance

• Q1 2025 revenue guidance is $121–$127 million, with operating income of $10.2–$12.8 million and EPS of $0.12–$0.16.

• Effective tax rate projected at 25% for 2025.

• U.S. onshore activity projected to be flat to slightly down; international growth expected in the Middle East, South Atlantic Margin, North Sea, and Asia-Pacific.

• Reservoir Description Q1 2025 revenue expected at $82–$85 million; operating income $9–$10.7 million.

• Production Enhancement Q1 2025 revenue expected at $39–$42 million; operating income $1.1–$2 million.